论文部分内容阅读
随机把我院2011年10月-2012年10月收治的90例脑梗死患者随机分成尿激酶治疗组和常规治疗组,并观察两组治疗效果。结果尿激酶治疗组患者的治疗总有效率为91.1%,远远高于常规治疗组的71.1%,两组差异比较具有统计学意义(P<0.05);尿激酶治疗组患者治疗后神经功能缺损评分明显低于常规治疗组,两组差异比较具有统计学意义(P<0.05);其中尿激酶治疗组不良反应率为4.4%,低于常规治疗组的8.9%,但两组差异比较无统计学意义(P>0.05)。尿素酶治疗脑梗死疗效肯定,值得推广。
Ninety patients with cerebral infarction who were admitted to our hospital from October 2011 to October 2012 were randomly divided into urokinase group and conventional treatment group. The therapeutic effect was observed in both groups. Results The total effective rate of urokinase treatment group was 91.1%, which was significantly higher than that of the conventional treatment group (71.1%), the difference between the two groups was statistically significant (P <0.05). After treatment, the urokinase treatment group had neurological deficits The score was significantly lower than the conventional treatment group, the difference between the two groups was statistically significant (P <0.05); the adverse reaction rate of urokinase treatment group was 4.4%, 8.9% lower than the conventional treatment group, but there was no statistical difference between the two groups Significance (P> 0.05). Efficacy of urease for the treatment of cerebral infarction is worthy of promotion.